Cheryl A. Smyth
University of Alabama at Birmingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cheryl A. Smyth.
Transplantation | 2001
Juan L. Contreras; Guadalupe Bilbao; Cheryl A. Smyth; Xiao L. Jiang; Devin E. Eckhoff; Stacie Jenkins; Francis T. Thomas; David T. Curiel; Judith M. Thomas
Isolated pancreatic islet transplantation is a promising alternative to conventional insulin-dependent diabetes treatment but is not yet a practical clinical therapy. In the first few days after pancreatic islet transplantation, substantial donor pancreatic islet dysfunction and apoptosis commonly occur. Islet apoptosis has been documented after extracellular matrix disruption and exposure to proinflammatory cytokines, and during hypoxia before islet revascularization and rejection. These studies show that targeting the apoptosis pathway by adenoviral-mediated gene transfer of the anti-apoptotic Bcl-2 gene exerts a major cytoprotective effect on isolated macaque pancreatic islets. Bcl-2 transfection ex vivo protects these islets from apoptosis induced by disruption of the islet extracellular matrix during pancreatic digestion. Additionally, overexpression of Bcl-2 confers long-term, stable protection and maintenance of functional islet mass after transplantation of macaque islets into diabetic severe combined immunodeficency mice. Notably, genetic modification of pancreatic islets also reduced the islet mass required to achieve stable euglycemia. Ex vivo gene transfer of anti-apoptotic genes has potential as a therapeutic approach to both minimize loss of functional islet mass after transplant and reduce the high donor islet requirement currently needed for successful stable reversal of insulin-dependent diabetes.
Gene Therapy | 1998
Kurt R. Zinn; Joanne T. Douglas; Cheryl A. Smyth; Hong-Gang Liu; Qi Wu; V. N. Krasnykh; John D. Mountz; David T. Curiel; James M. Mountz
Hepatic sequestration of systemically administered adenoviral vectors reduces the number of viral particles available for delivery to other tissues. The biological basis of this phenomenon was investigated using a new in vivo technique which permitted imaging in real time. Recombinant adenovirus serotype 5 knob (Ad5K) was radiolabeled with the gamma-emitter 99mTc (half-life = 6 h). Scatchard analysis of the 99mTc-Ad5K showed specific, high-affinity binding to U293 cells (Kd = 1.4 ± 0.5 nM), demonstrating that the radiolabeling process had no effect on receptor binding. In vivo dynamic imaging with an Anger gamma camera revealed that the liver binding followed an exponential rise to maximum, with a measured 100% extraction efficiency. Initially, the liver binding capacity was 3.1 ± 0.4 μg Ad5K, equivalent to approximately 17000 Ad5K molecules per liver cell. Liver binding was blocked by preincubation of Ad5K with neutralizing anti-Ad5K antibody; a 50% reduction in liver uptake was demonstrated by imaging. Unlabeled Ad5K was more effective in blocking liver uptake of 99mTc-Ad5K, whereas irrelevant unlabeled Ad3K had no effect. Imaging data for the liver uptake studies were in agreement with biodistribution determined by removing and measuring tissues. These data demonstrated that in vivo imaging is a sensitive tool for measuring changes to liver tropism. Similar imaging techniques can be applied to adenovirus vectors to measure specific targeting for gene therapy.
Arthritis & Rheumatism | 1999
Kurt R. Zinn; Tandra R. Chaudhuri; Cheryl A. Smyth; Qi Wu; Hong-Gang Liu; Martin Fleck; John D. Mountz; James M. Mountz
OBJECTIVE To determine the potential of an E-selectin-binding peptide (ESbp) to specifically bind activated endothelium in rheumatoid arthritis (RA) animal models. METHODS ESbp (KYDGDITWDQLWDLMK; 2,027 daltons) was labeled with biotin and 99mTc. The affinity of ESbp derivatives for E-selectin was measured by enzyme-linked immunosorbent assay. The binding of biotin-ESbp was compared with that of an anti-E-selectin antibody, by immunohistochemical analyses of human synovial sections and sections from the Mycoplasma pulmonis MRL-lpr/lpr mouse arthritis model. 99mTc-ESbp was sequentially imaged in vivo with a gamma camera in the rat adjuvant-induced arthritis model. RESULTS E-selectin expression was detected in human RA synovium and mouse arthritic synovium using biotin-ESbp. Both biotin-ESbp and 99mTc-labeled ESbp had high affinity for E-selectin (dissociation constant 2-5 nM). In vivo imaging showed specific binding of 99mTc-ESbp to the rat ankle joint prior to clinical manifestations of inflammation. CONCLUSION These results demonstrate that activated endothelium can be targeted with 99mTc-ESbp. The specificity of targeting can be used to evaluate up-regulation of E-selectin in RA models, and to follow changes in this up-regulation during treatment trials.
American Journal of Transplantation | 2002
Guadalupe Bilbao; Juan L. Contreras; Igor Dmitriev; Cheryl A. Smyth; Stacie Jenkins; Devin E. Eckhoff; Francis T. Thomas; Judith M. Thomas; David T. Curiel
The ability to transfer immunoregulatory, cytoprotective, or antiapoptotic genes into pancreatic islets (PIs) may allow enhanced post‐transplantation survival. The available gene transfer vectors differ greatly in their ability to infect and express genes in different cell types. One limitation associated with the use of viral vectors is related to the virus reliance on the presence of its primary binding site. Tropism of the viral vectors can be altered using retargeting strategies. Results on phage biopanning proved that the RGD motif has in vivo targeting capabilities. This motif interacts especially with cellular integrins of the αVβ3 and αVβ5 types, highly expressed on pancreatic islets. In this report, we have explored the utility of a retargeted adenovirus vector (Ad) containing an RGD motif in the HI loop of the fiber knob in order to improve the infection efficiency to intact isolated nonhuman primate PIs and reduce toxicity after the genetic modification. Nonhuman primate PIs were isolated by a semi‐automated technique. Steptozotocin‐induced diabetic mice with severe combined immunodeficiency disease (SCID) were used as recipients. A recombinant Ad containing a heterologous RGD peptide and expressing luciferase (AdRGDLuc) or green fluorescent protein (AdRGDGFP) were generated in our laboratory. Similar Ads without the RGD peptide were used as a control (AdLuc and AdGFP). Higher transfection efficiency was demonstrated using AdRGDGFP compared with AdGFP (> 80% of the islet cells were infected at 10 particle‐forming units (pfu)/cell using AdRGDGFP vs. 7% after infection with AdGFP). More than 90% of the infected cells were insulin‐producing cells. Significantly higher transgene expression was demonstrated after infection with AdRGDLuc compared with AdLuc at different titers. Analysis of the glucose‐stimulated insulin response demonstrated better performance of PI transfected with AdRGDLuc at low titers (10 pfu/cell in order to achieve > 80% transfection efficiency) compared with AdLuc at high titers. Finally, long‐term euglycemia (> 250 d) was observed in 89% of the animals that received PI infected with AdRGDLuc compared with none of the animals that received PI infected with AdLuc. The present study provides new information about the possibility of tropism modification of Ad vectors to increase the transfection efficiency and transgene expression to isolated PI. Incorporation of the RGD sequence in the HI loop of the fiber knob allows highly efficient transfection efficiency to nonhuman primate insulin‐producing cells and adequate long‐term function of the β‐cell after transplantation.
Transplantation | 2003
Juan L. Contreras; Hongju Wu; Cheryl A. Smyth; Christopher Eckstein; Carlton J. Young; Toshiro Seki; Guadalupe Bilbao; David T. Curiel; Devin E. Eckhoff
Background. New strategies for improving durable functional islet mass will be instrumental in facilitating islet transplantation as a cure for type 1 diabetes mellitus. The ability to transfer immunoregulatory or cytoprotective genes into pancreatic islets may enhance survival. Adenoviral vectors (Ad5) have been used widely to deliver therapeutic genes to different tissues. Limitations associated with the use of Ad5 for gene therapy are related to the reliance of the virus on the presence of its primary receptor, the transient nature of the transgene expression, and the immediate inflammatory and immune response elicited by the infection. Because the arginine‐glycine‐aspartame (RGD) and polylysine (pK7) motifs have been shown to enhance Ad5 infection through an Ad5 receptor‐independent pathway, we hypothesized that they could act additively to improve infectivity and reduce toxicity to isolated human pancreatic islets (IHPI). Methods. Hand‐picked IHPI were infected with nonmodified Ad5, single‐modified Ad5 with RGD (Ad5RGD) or pK7 (ad5pK7), and Ad5RGDpK7. Transfection efficiency was evaluated by green fluorescent protein and luciferase expression. Apoptosis was assessed using a quantitative assay, activation of caspase 3 by a colorimetric assay, nuclear factor (NF)‐&kgr;B nuclear translocation using a promoter‐luciferase NF‐&kgr;B responsive construct, regulated on activation normal T‐cell expressed and secreted (RANTES) by enzyme‐linked immunosorbent assay. In vivo functionality was evaluated after transplantation into diabetic nonobese diabetic severe combined immunodeficiency mice. Results. Compared with unmodified and singlymodified Ad5 vectors, Ad5RGDpK7 demonstrated the highest infectivity. After the infection of IHPI with adenoviral vectors using the minimal dose required to infect greater than 80% of the islet cells (Ad5, 500 viral particles [VP]/cell; Ad5RGD and Ad5pK7, 10 VP/cell; Ad5RGDpK7, 0.1 VP/cell), islets infected with Ad5RGDpK7 presented a significant reduction in apoptosis, NF‐&kgr;B nuclear translocation, RANTES expression, and higher glucose disposal rate; reduced Ad5‐driven specific Th1 and antibody response were also observed. Conclusions. Ad5RGDpK7 exhibited higher transfection efficiency, allowing a significant reduction in the viral dose required to infect greater than 80% of the islet cells. The reduction in the viral dose was associated with reduced toxicity, inflammation, and immune responses related to Ad5 infection. This strategy may thus be used to successfully modify isolated pancreatic islets.
Diabetes | 2003
Juan L. Contreras; Christopher Eckstein; Cheryl A. Smyth; Marty T. Sellers; Mario Vilatobá; Guadalupe Bilbao; Firoz G. Rahemtulla; Carlton J. Young; J. Anthony Thompson; Irshad H. Chaudry; Devin E. Eckhoff
Diabetes | 2004
Juan L. Contreras; Christopher Eckstein; Cheryl A. Smyth; Guadalupe Bilbao; Mario Vilatobá; Sharman E. Ringland; Carlton J. Young; J. Anthony Thompson; José A. Fernández; Devin E. Eckhoff
Surgery | 2005
Mario Vilatobá; Christopher Eckstein; Guadalupe Bilbao; Cheryl A. Smyth; Stacie Jenkins; J. Anthony Thompson; Devin E. Eckhoff; Juan L. Contreras
Diabetes | 2001
Judith M. Thomas; Juan L. Contreras; Cheryl A. Smyth; Andrew L. Lobashevsky; Stacie Jenkins; William J. Hubbard; Devin E. Eckhoff; Scott Stavrou; David M. Neville; Francis T. Thomas
Transplantation | 2002
Juan L. Contreras; Cheryl A. Smyth; Guadalupe Bilbao; Carlton J. Young; J. Anthony Thompson; Devin E. Eckhoff